Longtime Johnson & Johnson CEO Bill Weldon said this week that he will step down from his role in April. His tenure was marked by “recalls of everything from Tylenol to Benadryl that has cost the company hundreds of millions of dollars and consumers' trust,” said the Associated Press.
Alex Gronsky, vice chairman, will become the company's chief executive two months from now.
It remains to be seen what messages J&J will emphasize in the wake of Welden's retirement. However, it's a good bet it will stress the safety and reliability of its products as it moves forward.